orlistat and Essential-Hypertension

orlistat has been researched along with Essential-Hypertension* in 1 studies

Other Studies

1 other study(ies) available for orlistat and Essential-Hypertension

Article	Year
Orlistat, an under-recognised cause of progressive renal impairment. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28 Suppl 4 Obesity is an emerging risk factor for chronic kidney disease (CKD) in the developed world. Orlistat, an intestinal lipase inhibitor, used in the treatment of obesity is available as an over-the-counter medication across the European union and in many countries worldwide. It is associated with acute kidney injury (AKI). We present three adults, followed up from 1 to 6 years, who developed de novo or worsening renal impairment while on orlistat. Stopping the drug halted progression, but did not reverse the degree of renal impairment at presentation. Topics: Acute Kidney Injury; Aged; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Disease Progression; Essential Hypertension; Female; Humans; Hypertension; Lactones; Lipase; Male; Middle Aged; Obesity; Orlistat; Prognosis; Risk Factors	2013

Article

Year

Orlistat, an under-recognised cause of progressive renal impairment.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28 Suppl 4

Obesity is an emerging risk factor for chronic kidney disease (CKD) in the developed world. Orlistat, an intestinal lipase inhibitor, used in the treatment of obesity is available as an over-the-counter medication across the European union and in many countries worldwide. It is associated with acute kidney injury (AKI). We present three adults, followed up from 1 to 6 years, who developed de novo or worsening renal impairment while on orlistat. Stopping the drug halted progression, but did not reverse the degree of renal impairment at presentation.

Topics: Acute Kidney Injury; Aged; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Disease Progression; Essential Hypertension; Female; Humans; Hypertension; Lactones; Lipase; Male; Middle Aged; Obesity; Orlistat; Prognosis; Risk Factors

2013